Q2 2026 saw 4% revenue growth and 8% EPS growth, with strong momentum in cloud and subscription businesses. The acquisition of ArisGlobal strengthens the life sciences platform and AI capabilities, while full-year guidance is reaffirmed. Cash flow and margins remain robust.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.